Ratings by Brookline Capital Markets (Kumaraguru Raja)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | Cellectar Biosciences | CLRB | New Coverage | Buy (N/A) |
2.77 (2.63) |
-5.05% | Details | |
| 6/29/2026 | Edesa Biotech Inc. | EDSA | New Coverage | Buy (N/A) |
8.19 (6.81) |
-16.85% | Details | |
| 4/7/2026 | Unicycive Therapeutics | UNCY | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2025 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
2.13 (3.81) |
78.87% | Details | |
| 8/28/2025 | I-Mab | IMAB | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2025 | Forte Biosciences Inc. | FBRX | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2025 | Intensity Therapeutics, Inc. | INTS | Upgrade | Buy (Hold) |
0.27 (4.92) |
1722.22% | Details | |
| 6/26/2025 | Adial Pharmaceuticals Inc | ADIL | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2025 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
2.55 (2.38) |
-6.67% | Details | |
| 5/19/2025 | Intensity Therapeutics, Inc. | INTS | Downgrade | Hold (Buy) |
0.42 (0.27) |
-35.71% | Details | |
| 2/27/2025 | I-Mab | IMAB | New Coverage | Buy (N/A) |
0.95 (4.63) |
387.37% | Details | |
| 12/24/2024 | Medicus Pharma Ltd. | MDCX | New Coverage | Buy (N/A) |
2.58 (0.37) |
-85.66% | Details | |
| 12/18/2024 | Quince Therapeutics Inc. | QNCX | New Coverage | Buy (N/A) |
1.91 (17.25) |
803.14% | Details | |
| 9/20/2024 | Intensity Therapeutics, Inc. | INTS | New Coverage | Buy (N/A) |
4.08 (0.42) |
-89.71% | Details | |
| 8/22/2024 | OS Therapies, Inc | OSTX | New Coverage | Buy (N/A) |
4.04 (1.62) |
-59.9% | Details | |
| 6/7/2024 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
2.73 (3.73) |
36.63% | Details | |
| 5/29/2024 | Forte Biosciences Inc. | FBRX | New Coverage | Buy (N/A) |
0.65 (44.12) |
6687.69% | Details | |
| 12/19/2023 | Cyclacel Pharmaceuticals | CYCC | Downgrade | Hold (Buy) |
3.69 (6.37) |
72.63% | Details | |
| 12/7/2023 | Hepion Pharma | HEPA | Downgrade | Hold (Buy) |
3.24 (0.32) |
-90.12% | Details | |
| 8/30/2023 | Outlook Therapeutics Incs. | OTLK | Downgrade | Hold (Buy) |
1.41 (1.55) |
9.93% | Details | |
| 3/22/2023 | 9 Meter Biopharma | NMTR | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Cyclacel Pharmaceuticals | CYCC | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2023 | Biocept | BIOC | Downgrade | Hold (Buy) |
0.56 (0.43) |
-23.21% | Details | |
| 12/29/2022 | Outlook Therapeutics Incs. | OTLK | Maintain | Buy (N/A) |
|
Details | ||
| 10/25/2022 | 9 Meter Biopharma | NMTR | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2022 | Biocept | BIOC | Maintain | Buy (N/A) |
|
Details | ||
| 7/6/2022 | Veru, Inc. | VERU | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2022 | Veru, Inc. | VERU | Maintain | Buy (N/A) |
|
Details | ||
| 1/25/2022 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 1/19/2022 | Dare Bioscience | DARE | New Coverage | Buy (N/A) |
1.62 (1.15) |
-29.01% | Details | |
| 10/13/2021 | Adial Pharmaceuticals Inc | ADIL | New Coverage | Buy (N/A) |
3.74 (2.83) |
-24.33% | Details | |
| 10/8/2021 | Biocept | BIOC | New Coverage | Buy (N/A) |
3.83 (0.43) |
-88.77% | Details | |
| 9/21/2021 | Dermata Therapeutics In | DRMA | New Coverage | Buy (N/A) |
4.87 (1.35) |
-72.28% | Details | |
| 9/3/2021 | Forte Biosciences Inc. | FBRX | Downgrade | Hold (Buy) |
28.59 (0.65) |
-97.73% | Details | |
| 8/24/2021 | SCYNEXIS | SCYX | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2021 | Outlook Therapeutics Incs. | OTLK | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2021 | Atreca Inc. | BCEL | Maintain | Buy (N/A) |
|
Details | ||
| 5/19/2021 | Veru, Inc. | VERU | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2021 | 9 Meter Biopharma | NMTR | New Coverage | Buy (N/A) |
1.31 (0.07) |
-94.66% | Details | |
| 3/24/2021 | Forte Biosciences Inc. | FBRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/23/2021 | Hepion Pharma | HEPA | Maintain | Buy (N/A) |
|
Details | ||
| 3/12/2021 | NLS Pharmaceutics | NLSP | New Coverage | Buy (N/A) |
2.82 (0.76) |
-73.05% | Details | |
| 3/4/2021 | Vaxart Inc. | VXRT | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2021 | Caladrius Biosciences | CLBS | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2021 | SCYNEXIS | SCYX | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2021 | Veru, Inc. | VERU | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2021 | CNS Pharmasceuticals Inc. | CNSP | New Coverage | Buy (N/A) |
1.80 (5.09) |
182.78% | Details | |
| 12/29/2020 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2020 | Veru, Inc. | VERU | Maintain | Buy (N/A) |
|
Details | ||
| 12/7/2020 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2020 | Chiasma | CHMA | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2020 | Forte Biosciences Inc. | FBRX | New Coverage | Buy (N/A) |
26.69 (44.12) |
65.31% | Details | |
| 8/20/2020 | FSD Pharma Inc | HUGE | New Coverage | Buy (N/A) |
2.76 (0.09) |
-96.74% | Details | |
| 8/13/2020 | BioCardiAa | BCDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/15/2020 | Celsion Corp | CLSN | Maintain | Buy (N/A) |
|
Details | ||
| 5/22/2020 | Caladrius Biosciences | CLBS | New Coverage | Buy (N/A) |
1.93 (0.43) |
-77.72% | Details | |
| 5/19/2020 | Cyclacel Pharmaceuticals | CYCC | New Coverage | Buy (N/A) |
4.12 (6.37) |
54.61% | Details | |
| 5/11/2020 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2020 | Edesa Biotech Inc. | EDSA | New Coverage | Buy (N/A) |
2.16 (8.19) |
279.17% | Details | |
| 3/13/2020 | Armata Pharmaceuticals | ARMP | New Coverage | Buy (N/A) |
3.20 (3.97) |
24.06% | Details | |
| 2/13/2020 | Veru, Inc. | VERU | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2020 | SCYNEXIS | SCYX | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2020 | SCYNEXIS | SCYX | Maintain | Buy (N/A) |
|
Details | ||
| 11/26/2019 | BioCardia | BCDA | New Coverage | Buy (N/A) |
3.51 (0.91) |
-74.07% | Details | |
| 11/22/2019 | Hepion Pharma | HEPA | New Coverage | Buy (N/A) |
3.39 (0.32) |
-90.56% | Details | |
| 11/11/2019 | Chiasma | CHMA | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2019 | Atreca Inc. | BCEL | New Coverage | Hold (N/A) |
17.60 (0.09) |
-99.49% | Details | |
| 8/20/2019 | SCYNEXIS | SCYX | New Coverage | Buy (N/A) |
1.08 (4.48) |
314.81% | Details | |
| 8/15/2019 | Vaxart Inc. | VXRT | New Coverage | Buy (N/A) |
0.67 (0.32) |
-52.24% | Details | |
| 7/30/2019 | Cellectar Biosciences | CLRB | New Coverage | Buy (N/A) |
2.15 (2.77) |
28.84% | Details | |
| 7/30/2019 | Veru, Inc. | VERU | New Coverage | Buy (N/A) |
2.28 (2.56) |
12.28% | Details | |
| 7/30/2019 | Progenics Pharmaceuticals | PGNX | New Coverage | Buy (N/A) |
5.18 (4.10) |
-20.85% | Details | |
| 7/25/2019 | Celsion Corp | CLSN | New Coverage | Buy (N/A) |
1.77 (1.96) |
10.73% | Details | |
| 7/25/2019 | Chiasma | CHMA | New Coverage | Buy (N/A) |
7.86 (3.79) |
-51.78% | Details | |
| 2/6/2019 | Chiasma | CHMA | New Coverage | Buy (N/A) |
3.42 (7.86) |
129.82% | Details | |
| 11/28/2018 | Rexahn Pharmaceuticals Inc. | RNN | New Coverage | Buy (N/A) |
1.11 (5.24) |
372.07% | Details | |
| 11/21/2018 | Cellectar Biosciences | CLRB | New Coverage | Buy (N/A) |
2.20 (2.15) |
-2.27% | Details | |
| 11/20/2018 | Celsion Corp | CLSN | New Coverage | Buy (N/A) |
1.88 (1.77) |
-5.85% | Details | |
| 8/15/2018 | Acer Therapeutics | ACER | Maintain | Buy (N/A) |
|
Details |
